Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01451346 | Study in Patients With Mild to Moderate Psoriasis | PHASE1 | COMPLETED | 47 | — | — | Jan 1, 2008 | Aug 1, 2011 | Oct 13, 2011 | 1 | Ireland |
The PASI score stands for Psoriasis Area and Severity Index. This tool allows researchers to put an objective number on what would otherwise be a very subjective idea: how bad is a person's psoriasis. To make up the score, the three features of a psoriatic plaque (redness) scaling and thickness are each assigned a number from 0 to 4 with 4 being worst. Then the extent of involvement of each region of the body is scored from 0 to 6. Adding up the scores give a range of 0 to 72
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo sachets contained 5 grams of Maltodextrin only. |
| B Infantis 35624 | EXPERIMENTAL | Each 5gram freeze-dried powder contained ≥1\*1010 Colony forming units (CFU) of B. infantis 35624/sachet. |
| Name | Type | Description |
|---|---|---|
| B. Infantis 35624 | DIETARY_SUPPLEMENT | One sachet daily for 12 weeks |
Inclusion Criteria: * Subjects diagnosed with mild to moderate psoriasis as defined by the clinician, * Has a Psoriasis Area and Severity Index{PASI} of less than 20, * Male or female subjects, * Aged between 18-60 years of age, * Non-pregnant female and must agree to use adequate method of contrac...